Arrowhead Pharma (ARWR) PT Raised to $40 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street slides as AI cash burn worries spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $59.31 -1.95%
Rating Summary:
18 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 49 | New: 9
Rating Summary:
18 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 49 | New: 9
Join SI Premium – FREE
Morgan Stanley analyst Michael E Ulz raised the price target on Arrowhead Pharma (NASDAQ: ARWR) to $40.00 (from $37.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Freedom Broker Downgrades RPC Inc. (RES) to Sell
- Veralto Corp. (VLTO) PT Raised to $135 at Jefferies, 'Accelerating Core Growth into 2027'
- Regeneron Pharma (REGN) PT Raised to $875 at Baird
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
